Phases, active trials: Phase 1: 36, Phase 2: 57, Phase 3: 63, Other: 13
GSK's pipeline spans oncology, specialty medicines, and vaccines. In oncology, dostarlimab (Jemperli), a PD-1 inhibitor with approval in dMMR endometrial cancer, is expanding into multiple solid tumor indications. Their BCMA-targeting ADC, belantamab mafodotin (Blenrep), initially approved and then voluntarily withdrawn pending new trial data, is being re-evaluated in combination trials in multiple myeloma. In gynecologic oncology, niraparib (Zejula) for ovarian cancer is progressing through combination trials. GSK's vaccine pipeline is one of the industry's strongest. Shingrix (shingles), Arexvy (RSV), and next-generation pandemic influenza vaccines represent major development investments. In respiratory/inflammation, Nucala (mepolizumab, IL-5) is expanding across eosinophilic conditions.
- Oncology (PD-1, BCMA/ADC, PARP inhibitor)
- Vaccines (RSV, influenza, meningococcal)
- Respiratory / inflammation (IL-5, COPD)
- HIV (long-acting cabotegravir)
- Rare disease
- Jemperli (dostarlimab): PD-1, gynecologic/dMMR cancers
- Blenrep (belantamab mafodotin): BCMA ADC, myeloma (combination trials)
- Zejula (niraparib): PARP inhibitor, ovarian cancer
- Nucala (mepolizumab): IL-5, eosinophilic asthma/EGPA
- Arexvy: RSV vaccine, adults 60+
- GSK3745417: STING agonist, solid tumors
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other… NCT07277270 | Primary completion moved at least 1 year 7 months later | Recruiting |
19 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants… NCT06521567 | Oct 13, 2026 · Estimated | Phase 1/2 |
16 more on the Completions page. See the calendar →
Monitor the GSK (GlaxoSmithKline) pipeline daily
Get a daily digest when GSK (GlaxoSmithKline) registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Multiple Myeloma | 20 |
| Asthma | 12 |
| Neoplasms | 9 |
| Gastrointestinal Neoplasms | 7 |
| Pulmonary Disease, Chronic Obstructive | 7 |
| Neoplasms, Endometrial | 5 |
| Non-alcoholic Fatty Liver Disease | 5 |
| Ovarian Neoplasms | 5 |
GSK's Jemperli re-expansion program, building on the dMMR endometrial approval into broader MSI-high/dMMR tumor types and combination regimens, generates consistent new oncology registrations. Their PARP inhibitor niraparib combination trials are closely followed in gynecologic oncology. The belantamab combination re-introduction is one of the most watched programs in multiple myeloma.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to GSK (GlaxoSmithKline)'s registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: GSK (GlaxoSmithKline) may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your GSK (GlaxoSmithKline) pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study to Evaluate the Immune Response and Safety of a Vaccine Against… NCT07851246 | Recruiting | Trial sites expanded: 0 → 12 locations | 2026-10-10 |
| A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart)… NCT07782957 | Recruiting | Trial sites expanded: 1 → 4 locations | 2026-10-10 |
| Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta… NCT06372496 | Active, Not Recruiting | Results posted: 2026-10-06 | 2026-10-07 |
| A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants… NCT07585266 | Recruiting | Trial sites expanded: 58 → 72 locations | 2026-10-06 |
| Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic… NCT06959095 | Recruiting | Interventions modified | 2026-10-06 |
Each trial page shows every change DataLookout has recorded for that trial.